Kasper, Siegfried http://orcid.org/0000-0001-8278-191X
Volz, Hans-Peter
Möller, Hans-Jürgen
Schläfke, Sandra
Klement, Stephan
Anghelescu, Ion-George
Seifritz, Erich
Funding for this research was provided by:
Dr. Willmar Schwabe
Medical University of Vienna
Article History
Received: 29 December 2023
Accepted: 16 February 2024
First Online: 1 April 2024
Declarations
:
: S. Ka. served in the past 3 years Dr Kasper as a consultant or on advisory boards for Angelini, Biogen, Boehringer, Esai, Janssen, IQVIA, Mylan, Recordati, Rovi, Sage and Schwabe; and he has served on speakers bureaus for Angelini, Aspen Farmaceutica S.A., Biogen, Janssen, Recordati, Schwabe, Servier, Sothema, and Sun Pharma. H.-P. V received grants/speaker honoraria from Lundbeck, Pfizer, Schwabe (Spitzner), Bayer, Janssen, neuraxpharm, AstraZeneca. H.-J. M. has received grant/research support, consulting fees and honoraria within the last years from AstraZeneca, Lundbeck, Otsuka, and Schwabe. S. S. and S. K. are employees of Dr. Willmar Schwabe GmbH & Co. KG, the sponsor of the study. I.G. A. served as a consultant, on advisory boards or as a speaker for Aristo Pharma, Dr. Wilmar Schwabe, Janssen Pharmaceutica, Merck Pharma, Recordati Pharma. E. S. received in the last three years grants from Swiss National Science Foundation and University of Zürich, and honoraria for advise and educational activities from Lundbeck, Schwabe, Janssen, Otsuka, Mepha Pharma, Otsuka Pharma, Recordati, OM Pharma, Takeda, Sunovion Pharma and Angelini.